| . | Combination lipid-lowering therapy (N = 6215) . | High-intensity atorvastatin monotherapy (N = 25 778) . | Risk difference (95% CI)a . | Hazard ratio (95% CI)b . | P-value . |
|---|---|---|---|---|---|
| Discontinuation of statin | 519 (8.4) | 2571 (10.0) | −1.6 (−2.5 to −0.8) | 0.81 (0.73−0.90) | <0.001 |
| New-onset diabetes requiring medicationc | 237/3370 (7.0) | 1253/14 244 (8.8) | −1.7 (−2.9 to −0.6) | 0.80 (0.70−0.92) | 0.002 |
| Rhabdomyolysis | 14 (0.2) | 90 (0.3) | −0.1 (−0.3 to 0.1) | 0.80 (0.47−1.34) | 0.390 |
| Cholecystectomy | 71 (1.1) | 236 (0.9) | 0.2 (0.0 to 0.5) | 1.27 (0.96−1.70) | 0.098 |
| Cancer diagnosis | 246 (4.0) | 1037 (4.0) | 0.0 (−0.6 to 0.5) | 0.98 (0.84−1.14) | 0.799 |
| . | Combination lipid-lowering therapy (N = 6215) . | High-intensity atorvastatin monotherapy (N = 25 778) . | Risk difference (95% CI)a . | Hazard ratio (95% CI)b . | P-value . |
|---|---|---|---|---|---|
| Discontinuation of statin | 519 (8.4) | 2571 (10.0) | −1.6 (−2.5 to −0.8) | 0.81 (0.73−0.90) | <0.001 |
| New-onset diabetes requiring medicationc | 237/3370 (7.0) | 1253/14 244 (8.8) | −1.7 (−2.9 to −0.6) | 0.80 (0.70−0.92) | 0.002 |
| Rhabdomyolysis | 14 (0.2) | 90 (0.3) | −0.1 (−0.3 to 0.1) | 0.80 (0.47−1.34) | 0.390 |
| Cholecystectomy | 71 (1.1) | 236 (0.9) | 0.2 (0.0 to 0.5) | 1.27 (0.96−1.70) | 0.098 |
| Cancer diagnosis | 246 (4.0) | 1037 (4.0) | 0.0 (−0.6 to 0.5) | 0.98 (0.84−1.14) | 0.799 |
A 95% confidence interval (CI) for absolute risk reduction attributed to each treatment was calculated.
Cox proportional hazard models were used to obtain adjusted hazard ratio, 95% CI, and P-values by defining high-intensity atorvastatin monotherapy as the reference arm.
Incidence of new-onset diabetes requiring medication was assessed for participants without prior diabetes history at enrolment.
| . | Combination lipid-lowering therapy (N = 6215) . | High-intensity atorvastatin monotherapy (N = 25 778) . | Risk difference (95% CI)a . | Hazard ratio (95% CI)b . | P-value . |
|---|---|---|---|---|---|
| Discontinuation of statin | 519 (8.4) | 2571 (10.0) | −1.6 (−2.5 to −0.8) | 0.81 (0.73−0.90) | <0.001 |
| New-onset diabetes requiring medicationc | 237/3370 (7.0) | 1253/14 244 (8.8) | −1.7 (−2.9 to −0.6) | 0.80 (0.70−0.92) | 0.002 |
| Rhabdomyolysis | 14 (0.2) | 90 (0.3) | −0.1 (−0.3 to 0.1) | 0.80 (0.47−1.34) | 0.390 |
| Cholecystectomy | 71 (1.1) | 236 (0.9) | 0.2 (0.0 to 0.5) | 1.27 (0.96−1.70) | 0.098 |
| Cancer diagnosis | 246 (4.0) | 1037 (4.0) | 0.0 (−0.6 to 0.5) | 0.98 (0.84−1.14) | 0.799 |
| . | Combination lipid-lowering therapy (N = 6215) . | High-intensity atorvastatin monotherapy (N = 25 778) . | Risk difference (95% CI)a . | Hazard ratio (95% CI)b . | P-value . |
|---|---|---|---|---|---|
| Discontinuation of statin | 519 (8.4) | 2571 (10.0) | −1.6 (−2.5 to −0.8) | 0.81 (0.73−0.90) | <0.001 |
| New-onset diabetes requiring medicationc | 237/3370 (7.0) | 1253/14 244 (8.8) | −1.7 (−2.9 to −0.6) | 0.80 (0.70−0.92) | 0.002 |
| Rhabdomyolysis | 14 (0.2) | 90 (0.3) | −0.1 (−0.3 to 0.1) | 0.80 (0.47−1.34) | 0.390 |
| Cholecystectomy | 71 (1.1) | 236 (0.9) | 0.2 (0.0 to 0.5) | 1.27 (0.96−1.70) | 0.098 |
| Cancer diagnosis | 246 (4.0) | 1037 (4.0) | 0.0 (−0.6 to 0.5) | 0.98 (0.84−1.14) | 0.799 |
A 95% confidence interval (CI) for absolute risk reduction attributed to each treatment was calculated.
Cox proportional hazard models were used to obtain adjusted hazard ratio, 95% CI, and P-values by defining high-intensity atorvastatin monotherapy as the reference arm.
Incidence of new-onset diabetes requiring medication was assessed for participants without prior diabetes history at enrolment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
